Characteristics of ALL patients
| Patient | Age (years) | Immune Origin | Karyotype | Leukocytes × 109/liter | Status | Apaf-1/β-Actin Ratio | % Cell Death in Medium Alone (24 h) | % Cell Death in Bortezomib Treated (24 h) |
|---|---|---|---|---|---|---|---|---|
| ALL 1 | 3 | T cell | 46XX | 519 | CR | 0.4 | 88 | 96 |
| ALL 2 | 8 | T cell | 46,XX,del(11)(q23-25,del(12)(p13) | 588 | MRD | 0.5 | 40 | 82 |
| ALL 3 | 2.5 | B precursor | 46XYt(10:14) | 28.1 | CR2 | 0.7 | 94 | 98 |
| ALL 4 | 14 | T cell | 47,XY,+del(6)(q?21),t(11;19)(q23;pl13) | 144.8 | CR | 0.4 | 77 | 98 |
| ALL 5 | 16 | AML/T cell | 46XY,t(7;12)(p15;p13)[19]/46,XY[7] | 17.9 | MRD | 0.6 | 68 | 84 |
| ALL 6 | 11 | T cell | 46XY[27] | 4.1 | Relapsed diseased | 0.1 | 73 | 75 |
| ALL 7 | 6 | T cell | 46,XY,del(6)q2?1)23] | 316 | CR | 0.5 | 45 | 87 |
CR, complete remission; CR2, complete remission after first relapse; MRD, minimal residual disease.